A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Public ClinicalTrials.gov record NCT03662542. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Study identification
- NCT ID
- NCT03662542
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Enrollment
- 214 participants
Conditions and interventions
Conditions
Interventions
- Golimumab Dose 1 Drug
- Golimumab Dose 2 Drug
- Guselkumab Dose 1 Drug
- Guselkumab Dose 2 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 19, 2018
- Primary completion
- Nov 30, 2020
- Completion
- Nov 14, 2021
- Last update posted
- Dec 11, 2023
2018 – 2021
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Precision Research Institute | San Diego | California | 92114 | — |
| Peak Gastroenterology Associates | Colorado Springs | Colorado | 80907 | — |
| GCP Clinical Research | Tampa | Florida | 33609 | — |
| Gastrointestinal Specialists of Georgia | Marietta | Georgia | 30060 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| Chevy Chase Clinical Research | Chevy Chase | Maryland | 20815 | — |
| Woodholme Gastroenterology | Glen Burnie | Maryland | 21061 | — |
| Sierra Clinical Research | Las Vegas | Nevada | 89106 | — |
| The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Fargo Gastroenterology Clinic, PC | Fargo | North Dakota | 58103 | — |
| Texas Digestive Disease Consultants | Southlake | Texas | 76092 | — |
| Gastroenterology Associates of Tidewater | Chesapeake | Virginia | 23320 | — |
| Virginia Mason | Seattle | Washington | 98101 | — |
| Washington Gastroenterology, PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 68 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03662542, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 11, 2023 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03662542 live on ClinicalTrials.gov.